Clinical trial
Daclizumab to Treat HIV-Infected Patients
NCT00080431 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00080431 |
|---|---|
| Title | Daclizumab to Treat HIV-Infected Patients |
| Official title | An Open Label Trial to Assess Safety and Tolerability of Daclizumab in HIV-Infected Individuals |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Daclizumab |
| Enrollment | 10 |
| Start date | Mar 26, 2004 |
| Completion | Dec 28, 2007 |
| First posted | Mar 31, 2004 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: